CSRxP: BIG PHARMA HIKES PRICES ON NEARLY 250 PRESCRIPTION DRUGS IN LATEST ROUND OF MID-YEAR PRICE HIKES
Aug 25, 2026
Brand Name Drug Companies Maintain Business-as-Usual Approach to Price-Gouging… Read More
© 2026 CSRXP- All Rights Reserved
Statements
CSRxP APPLAUDS GROWING BIPARTISAN MOMENTUM TO LOWER PRESCRIPTION DRUG PRICES FOR AMERICAN CONSUMERS BY FOSTERING GREATER COMPETITION
Jul 23, 2026
Both Chambers of Congress and Lawmakers in Both Parties Advance Market-Based… Read More
CSRxP ENCOURAGES U.S. HOUSE ENERGY & COMMERCE COMMITTEE TO ADVANCE BIPARTISAN SOLUTIONS TO PROMOTE BIOSIMILAR COMPETITION, LOWER DRUG PRICES
Jul 20, 2026
Lawmakers Can Bring More Affordable Alternatives for American Consumers to… Read More
CSRxP: SENATE JUDICIARY COMMITTEE MUST REJECT BIG PHARMA’S FALSE RHETORIC ON INNOVATION, HOLD BRAND NAME MANUFACTURERS ACCOUNTABLE FOR PATENT ABUSE
Jul 13, 2026
Big Pharma’s Anti-Competitive Tactics That Extend Monopolies Are… Read More
CSRxP COMMENDS U.S. SENATE HELP COMMITTEE FOR PASSING BIPARTISAN, MARKET-BASED SOLUTIONS TO HOLD BIG PHARMA ACCOUNTABLE, LOWER DRUG PRICES
Jun 17, 2026
Committee Markup Advances Solutions to Crack Down on Big Pharma’s Patent… Read More
CSRxP ENCOURAGES HELP COMMITTEE TO ADVANCE BIPARTISAN, MARKET-BASED SOLUTIONS TO LOWER DRUG PRICES BY FOSTERING GREATER COMPETITION
Jun 16, 2026
Lawmakers Should Advance Biosimilar Red Tape Elimination Act, Medication… Read More
CSRxP: U.S. SUPREME COURT DECISION HELPS SAFEGUARDS CRITICAL PATHWAY FOR GENERIC COMPETITION
Jun 4, 2026
Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. Ruling Will Help Protect… Read More
CSRxP ENCOURAGES HOUSE JUDICIARY IP SUBCOMMITTEE TO ADVANCE BIPARTISAN, MARKET-BASED SOLUTIONS TO LOWER DRUG PRICES BY FOSTERING COMPETITION
Jun 3, 2026
Lawmakers Should Advance the ETHIC Act and Skinny Labels, Big Savings Act to… Read More
CSRxP ENCOURAGES HELP COMMITTEE TO BUILD MOMENTUM BEHIND BIPARTISAN SOLUTIONS TO LOWER PRESCRIPTION DRUG PRICES BY FOSTERING GREATER COMPETITION
Apr 15, 2026
Lawmakers Should Reject Big Pharma’s Debunked Rhetoric on Innovation… Read More
CSRxP STATEMENT ON PRESIDENT TRUMP’S STATE OF THE UNION ADDRESS
Feb 24, 2026
Administration and Congress Must Enact Market-Based Solutions to Hold Big… Read More
CSRxP: BIG PHARMA IS DRIVING HEALTH CARE INFLATION; CONGRESS MUST HOLD BIG PHARMA ACCOUNTABLE TO DELIVER AFFORDABILITY FOR AMERICAN PEOPLE
Feb 10, 2026
Campaign Encourages E&C Lawmakers to Focus on Big Pharma’s… Read More
CSRxP Statement on the Launch of TrumpRx
Feb 6, 2026
Campaign Appreciates Administration’s Commitment to Lowering Drug Prices,… Read More